Skip to main content
  • linkedin
New Website Coming Soon!
Hit enter to search or ESC to close
Close Search
Hepion PharmaceuticalsHepion Pharmaceuticals
Menu
  • About
    • Company Overview
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • Rencofilstat
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
    • Expanded Access Policy
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
    Hepion Pharmaceuticals

    Hepion in the News

     About Hepion
    Recent News
     Contact Us
    Hepion
    Hepion In Media Placements

    FDA Grants Orphan Drug Designations to VBI, Hepion Cancer Drugs [BioSpace]

    https://www.biospace.com/article/fda-approves-orphan-drug-designations-for-vbi-hepion-cancer-drugs/
    Hepion
    Hepion In Media Placements

    Tackling Liver Disease with a Multimodal Cyclophilin Inhibitor [Pharma’s Almanac]

    https://www.pharmasalmanac.com/articles/tackling-liver-disease-with-a-multimodal-cyclophilin-inhibitor?hs_preview=FMelfVXS-74910818711
    Hepion
    Hepion In Media Placements

    Can Hepion Pharmaceuticals Develop the First Treatment Approved For NASH? With Robert Foster, Pharm D, PhD [Biotech IQ]

    https://hepionpharma.com/wp-content/uploads/2022/05/47-can-hepion-pharmaceuticals-develop-the-first-treatment-approved-for-nash-with-robert-foster-pharm-d-phd.mp3
    https://hepionpharma.com/wp-content/uploads/2022/05/47-can-hepion-pharmaceuticals-develop-the-first-treatment-approved-for-nash-with-robert-foster-pharm-d-phd.mp3
    Read More
    Hepion
    Hepion In Media Placements

    Treating NASH and Other Fatty Liver Diseases Using Drugs Developed Around Cyclophilin Inhibition with Dr. Robert Foster Hepion Pharmaceuticals [Empowered Patient Podcast]

    https://hepionpharma.com/wp-content/uploads/2022/04/EP220322_Hepion.mp3
    https://hepionpharma.com/wp-content/uploads/2022/04/EP220322_Hepion.mp3
    Read More
    Hepion
    Hepion In Media Placements

    Q&A With Robert Foster, CEO of Hepion Pharmaceuticals [Pharm Exec]

    https://www.pharmexec.com/view/q-a-with-robert-foster-ceo-of-hepion-pharmaceuticals
    Hepion
    Hepion In Media Placements, Videos

    Hepion Pharmaceuticals CEO Robert Foster – Dash To Beat NASH (via Seeking Alpha)

    Read More
    Hepion
    Hepion In Media Placements, Videos

    Treating Chronic Liver Disease – Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster [via Seeking Alpha]

    Read More
    Hepion
    Hepion In Media Placements

    Hepion Striving to Repeat History by Developing its Second FDA-Approved Drug [via Benzinga]

    https://www.benzinga.com/general/biotech/21/03/20282078/hepion-striving-to-repeat-history-by-developing-its-second-fda-approved-drug
    Hepion
    Hepion In Industry News

    Health Matters: Edmonton drug and transplant technology both making waves in USA [via Global News]

    Read More
    Hepion
    Hepion In Industry News

    Breakthrough lupus drug ‘home grown’ by Edmonton doctor approved by FDA for use [via Global News]

    https://globalnews.ca/news/7670080/lupkynis-voclosporin-edmonton-drug-approved-lupus/
    • « Previous
    • 1
    • 2
    • 3
    • 4
    • 5
    • Next »
    Share Share Share

    Media Contact

    info@hepionpharma.com

    Tweets by Hepion Pharma
    Get Important News and Updates by Email Subscribe
    • linkedin

    © 2026 Hepion Pharmaceuticals | Disclaimer & Terms of Use | WDDI

    Close Menu
    • About
      • Company Overview
      • Executive Team
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Liver Disease
      • Overview
      • Non-alcoholic Steatohepatitis (NASH)
      • Hepatocellular Carcinoma (HCC)
      • Viral Hepatitis
    • AI-POWR™
    • Pipeline
      • Overview
      • Rencofilstat
      • Therapeutic Strategy
      • Clinical Trials
      • Publications
      • Expanded Access Policy
    • Newsroom
    • Investors
      • Investor Overview
      • Press Releases
      • Events
      • Presentations
      • Company Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact
      • Contact Us
      • Careers
    • linkedin